BEHAVIORAL CHANGES IN NONPSYCHOTIC VOLUNTEERS FOLLOWING THE ADMINISTRATION OF TARAXEIN, THE SUBSTANCE OBTAINED FROM SERUM OF SCHIZOPHRENIC PATIENTS
Abstract
Our studies concerned with the clinical effects of the administration of taraxein, a protein isolated from the serum of schizophrenic patients and not obtained from normal serum through our processing procedure, are summarized. In addition, we reported studies which suggest that this substance apparently is present in whole serum and is not a product activated through our processing procedure. One study concerned with the attempt to isolate taraxein following the administration of D-LSD-25 and a study describing the isolation of taraxein from patients receiving Thorazine were described. These experiments suggested that the LSD psychoses do not result from the formation of taraxein in nonpsychotic volunteers and that Thorazine does not produce clinical improvement by destroying or reducing levels of taraxein.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).